Los Angeles Capital Management LLC Trims Holdings in Organogenesis $ORGO

Los Angeles Capital Management LLC trimmed its holdings in Organogenesis (NASDAQ:ORGO) by 16.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 279,922 shares of the company’s stock after selling 56,048 shares during the quarter. Los Angeles Capital Management LLC owned about 0.22% of Organogenesis worth $1,025,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Organogenesis by 23.4% in the first quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock worth $19,144,000 after purchasing an additional 841,618 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of Organogenesis by 748.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 2,857,904 shares of the company’s stock worth $10,460,000 after buying an additional 2,520,941 shares during the last quarter. Driehaus Capital Management LLC purchased a new stake in shares of Organogenesis in the 1st quarter worth approximately $7,756,000. Invesco Ltd. increased its position in Organogenesis by 779.7% during the 1st quarter. Invesco Ltd. now owns 1,069,252 shares of the company’s stock valued at $4,619,000 after buying an additional 947,705 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in Organogenesis by 45.3% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 667,529 shares of the company’s stock valued at $2,884,000 after buying an additional 208,038 shares during the last quarter. Institutional investors own 49.57% of the company’s stock.

Organogenesis Price Performance

Shares of NASDAQ:ORGO opened at $6.48 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.88 and a current ratio of 3.32. The firm has a market cap of $822.38 million, a price-to-earnings ratio of -54.00 and a beta of 1.68. The business has a 50-day simple moving average of $4.52 and a two-hundred day simple moving average of $4.23. Organogenesis has a fifty-two week low of $2.61 and a fifty-two week high of $7.08.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. The firm had revenue of $150.86 million for the quarter, compared to the consensus estimate of $134.10 million. Organogenesis has set its FY 2025 guidance at EPS. On average, analysts expect that Organogenesis will post -0.07 earnings per share for the current year.

Analyst Ratings Changes

ORGO has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Organogenesis in a research note on Wednesday, October 8th. Cantor Fitzgerald increased their price objective on shares of Organogenesis from $7.00 to $9.00 and gave the company an “overweight” rating in a research report on Friday, August 8th. Wall Street Zen raised shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, BTIG Research reiterated a “buy” rating and set a $7.00 price target on shares of Organogenesis in a report on Friday, September 26th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $7.33.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.